GENFIT SA - €36.3 MILLION IN REVENUE FOR THE FIRST NINE MONTHS OF 2026 FROM ROYALTIES ON IPSEN’S SALES OF IQIRVO (ELAFIBRANOR), AN INCREASE
GENFIT SA - €36.3 MILLION IN REVENUE FOR THE FIRST NINE MONTHS OF 2026 FROM ROYALTIES ON IPSEN’S SAL
GENFIT SA - €36.3 MILLION IN REVENUE FOR THE FIRST NINE MONTHS OF 2026 FROM ROYALTIES ON IPSEN’S SAL